Efficacy of Shugan Hewei Decoction in treating chronic atrophic gastritis and its influence on gastric mucosal pathology.

BACKGROUND AND STUDY AIMS: To investigate the efficacy of Shugan Hewei Decoction in the treatment of chronic atrophic gastritis (CAG) and its effect on gastric mucosal pathology.

PATIENTS AND

METHODS

A total of 72 patients with CAG admitted from October 2022 to December 2023 were enrolled and divided into two groups using a random number table method. The control group (36 cases) was treated with oral Weifuchun, while the study group (36 cases) received oral Shugan Hewei Decoction. The two groups were compared in terms of total treatment effectiveness rate, incidence of adverse reactions, scores of primary and secondary symptoms (before and after treatment), gastric function indices (pepsinogenⅠ [PGⅠ], pepsinogenⅠ/pepsinogenⅡ [PGⅠ/PGⅡ], and gastrin-17 [G-17]), and scores of gastric mucosal pathological indices (intestinal metaplasia, glandular atrophy, and dysplasia).

RESULTS

The total treatment effectiveness rate in the study group was significantly higher than that in the control group, while the total incidence of adverse reactions was significantly lower (both P < 0.05). Before treatment, there were no significant differences between the two groups in scores of primary and secondary symptoms, gastric function indices, or scores of gastric mucosal pathological indices (all P > 0.05). After treatment, the study group showed significantly lower scores of primary and secondary symptoms and gastric mucosal pathological indices, as well as significantly higher gastric function indices compared with the control group (all P < 0.05).

CONCLUSION

Shugan Hewei Decoction exhibits favorable efficacy and high safety in the treatment of CAG. It can significantly improve the gastric mucosal pathological state, thus holding relatively high application value in CAG patients.